Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

by Zacks Equity Research

Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.

Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

by Zacks Equity Research

Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ALXN) Outperforming Other Medical Stocks This Year?

Alexion (ALXN) Collaborates With Stealth BioTherapeutics

by Zacks Equity Research

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

Kinjel Shah headshot

3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

ALXN vs. CBM: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ALXN vs. CBM: Which Stock Is the Better Value Option?

Alexion (ALXN) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Alexion is a Hot Takeover Target in the Biotech Sector

by Zacks Equity Research

Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.

Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

3 Reasons Growth Investors Will Love Alexion (ALXN)

by Zacks Equity Research

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

Ekta Bagri headshot

3 Big Biotech Stocks Worth Adding to Your Portfolio Now

by Ekta Bagri

We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

by Zacks Equity Research

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

by Zacks Equity Research

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

by Zacks Equity Research

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

ALXN or CBM: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. CBM: Which Stock Is the Better Value Option?

Sanghamitra Saha headshot

Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

by Zacks Equity Research

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

by Zacks Equity Research

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ALXN) Outperforming Other Medical Stocks This Year?